ReviewFrontiers in pharmacology2025
Progress of tanshinone IIA against respiratory diseases: therapeutic targets and potential mechanisms.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Diterpenes with Abietane and Clerodane Skeletons from the MexicanMolecules (Basel, Switzerland) · 2026Review
- Beyond energy production: targeting mitochondrial biogenesis in aging and cancer with phytochemical intervention.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Multi-omics elucidation of temporal patterns in tanshinone accumulation in Salvia miltiorrhiza.BMC plant biology · 2026Article
- A multifunctional ICAM1-directed MnO₂@ZIF8 nanoplatform with Tanshinone IIA synergistically reverses senescence and restores alveolar regeneration in septic lung injury.Journal of nanobiotechnology · 2026Article
- Viral Pathogens and Pulmonary Fibrosis: EMT-Driven Mechanisms and Insights From Traditional Chinese Medicine.Reviews in medical virology · 2026Review
- Multifaceted mechanisms of plant metabolites in pulmonary arterial hypertension: a critical review beyond vasodilation.Frontiers in pharmacology · 2026Review
- Tanshinone IIA inhibits malignant progression in a spontaneous breast cancer mouse model by attenuating tissue factor-mediated angiogenesis.Frontiers in pharmacology · 2026Article
- Intracellular Calcium as a Regulator of Polarization and Target Reprogramming of Macrophages.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The respiratory system stands as one of the eight pivotal systems within the human body, responsible for a range of essential functions. Primarily, it facilitates the absorption of oxygen from the external environment and the expulsion of carbon dioxide, thereby playing a crucial role in regulating the body's acid-base balance. Furthermore, it helps to maintain the stability of the internal environment, ensuring the smooth progression of normal metabolic processes and sustaining life activities. In the wake of the novel coronavirus pneumonia outbreak, respiratory diseases have continued to exhibit comparatively high morbidity and mortality rates, underscoring the urgent need for the discovery of novel therapeutic agents. Tanshinone IIA (Tan IIA), a bioactive chemical constituent derived from
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.